Life Science Investing ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program
Life Science Investing ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs
